Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
T.T. McDonald, G. Monteleone, S.L. Pender.
Recent developments in the immunology of inflammatory bowel disease.
Scand J Immunol, 51 (2000), pp. 2-9
[2.]
K.A. Papadakis, S.R. Targan.
Role of cytokines in the pathogenesis of inflammatory bowel disease.
Annu Rev Med, 51 (2000), pp. 289-298
[4.]
M.F. Neurath, C. Becker, K. Barbulescu.
Role of NF-kappaB in immune and inflammatory responses in the gut.
Gut, 43 (1998), pp. 856-860
[6.]
W.J. Sandborn, S.R. Targan.
Biologic therapy of inflammatory bowel disease.
Gastroenterology, 122 (2002), pp. 1592-1608
[7.]
S.R. Targan, S.B. Hanauer, S.J. Van Deventer, L. Mayer, D.H. Present, T. Braakman, et al.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.
N Engl J Med, 337 (1997), pp. 1029-1035
[8.]
D.H. Present, P. Rutgeerts, S. Targan, S.B. Hanauer, L. Mayer, R.A. Van Hogezan, et al.
Infliximab for the treatment of fistulas in patient's with Crohn's disease.
N Engl J Med, 340 (1999), pp. 1398-1405
[9.]
S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein, L.F. Mayer, S. Schreiber, J.F. Colombel, et al.
Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial.
Lancet, 359 (2002), pp. 1541-1549
[10.]
W.J. Sandborn, B.G. Feagan, S.B. Hanuer, D.H. Present, L.R. Sutherland, M.A. Kamm, et al.
An engeineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
Gastroenterology, 120 (2001), pp. 1330-1338
[11.]
F.H. Gordon, C.W. Lai, M.I. Hamilton, M.C. Allison, E.D. Srivastava, M.G. Fouweather, et al.
A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.
Gastroenterology, 121 (2001), pp. 268-274
[12.]
R.N. Fedorak, A. Gangl, C.O. Elson, P. Rutgeerts, S. Schreiber, G. Wild, et al.
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease.
Gastroenterology, 119 (2000), pp. 1473-1482
[13.]
S. Schreiber, R.N. Fedorak, O.H. Nielsen, G. Wild, C.N. Williams, S. Nikolaus, et al.
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease.
Gastroenterology, 119 (2000), pp. 1461-1472
[14.]
B.E. Sands, B.D. Winston, B. Salzberg, M. Sufdi, C. Barish, L. Wruble, et al.
Randomized controlled trial of recombinant human interleukin 11 in patients with active Crohn's disease.
Aliment pharmacol Ther, 16 (2002), pp. 399-406
[15.]
S. Schreiber, S. Nikolaus, H. Malchow, W. Kruis, H. Lochs, A. Raedler, et al.
Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
Gastroenterology, 120 (2001), pp. 1339-1346
[16.]
W.J. Sandborn, S.B. Hanauer, S. Katz, M. Safdi, D.G. Wolf, R.D. Baerg, et al.
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Gastroenterology, 121 (2001), pp. 1088-1094
[17.]
J.P. Hugot, M. Chamaillard, H. Zouali, S. Lesage, J.P. Cezard, J. Belaiche, et al.
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.
Nature, 411 (2001), pp. 599-603
[18.]
N. Kashiwagi, K. Sugimura, H. Koiwai, H. Yamamoto, T. Yoshikawa, A.R. Saniabadi, et al.
Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis.
Dig Dis Sci, 47 (2002), pp. 1334-1341
[19.]
P. Gionchetti, F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, et al.
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.
Gastroenterology, 119 (2000), pp. 305-309
[20.]
P. Gionchetti, C. Amadini, F. Rizzello, A. Venturi, V. Palmonari, C. Morselli, et al.
Probiotics: role in inflammatory bowel disease.
Dig Liver Dis, 34 (2002), pp. 58-62
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
